Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction
Small Cell Lung Cancer
DRUG: Liposome Irinotecan|DRUG: Platinum|DRUG: Tislelizumab|DRUG: Anlotinib
Progression-free survival (PFS), To evaluate the efficacy of anti-tumor, baseline up to approximately 6 months
Objective response rate (ORR), To evaluate the efficacy of anti-tumor, baseline up to approximately 6 months|Disease Control Rate (DCR), To evaluate the efficacy of anti-tumor, baseline up to approximately 6 months|overall survival (OS), To evaluate the efficacy of anti-tumor, baseline up to approximately 12 months|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], To identify the incidence of AE and SAE in clinical trial, From the initiation of the first dose to 14 days after the last dose
1. Irinotecan hydrochloride liposome injection combined with platinum and tislelizumab therapy in a 3-week treatment cycle , 4 cycles Drug: Liposome irinotecan(50mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle Drug: Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle Drug: Tislelizumab (200mg) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle
2. Maintenance treatment, to disease progression or AE Drug: Tislelizumab (200mg) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle Drug: Anlotinib (8mg) will be administered orally in a 3-week treatment cycle, once a day from day 1 to day 14 of each cycle